Navigation Links
High Urate Levels in Blood Linked to Reduced Parkinson's Risk

A new study has found that high levels of urate in the blood is linked to a reduced risk of Parkinson's disease.

The study, conducted by researchers at the Harvard School of Public Health (HSPH), was led by Marc Weisskopf, Assistant Professor of Environmental and Occupational Epidemiology.

Urate is a normal component of blood, and although high levels can lead to gout, urate might also have beneficial effects because it is a potent antioxidant.

Parkinson's disease is a chronic, progressive nerve disorder associated with destruction of brain cells producing dopamine, a neurotransmitter essential to the normal functioning of the central nervous system.

Marc Weisskop said that the results of the study provided the 'strongest evidence to date' that urate, a normal component of blood might also have beneficial effects in its capacity as a potent antioxidant.

High levels of urate in the blood can lead to gout.

"This is the strongest evidence to date that urate may protect against Parkinson's disease," said Weisskopf.

As a part of the study the researchers used data form the HSPH-based Health Professionals Follow-up Study, a population of male health professionals established in 1986. The study cohort included more than 18,000 men without Parkinson's disease who had provided blood samples between 1993 and 1995 and whose subsequent health status was followed.

The researchers found that men in the top quartile of blood urate concentration had 55 percent lower risk of developing Parkinson's disease than men in the bottom quartile. This difference was not explained by differences in age or other risk factors for Parkinson's disease.

The authors hypothesize that urate's antioxidant properties may help dampen the effects of oxidative stress, which appears to contribute to the progressive loss of the dopamine-producing brain cells that occurs in individuals wi th Parkinson's disease.

A team of researchers led by Alberto Ascherio, Associate Professor of Nutrition and Epidemiology at HSPH and senior author of the study and Michael Schwarzschild a movement disorder specialist at Massachusetts General Hospital then followed up on this clue and accessed the databases of two large, randomized studies conducted among patients with early Parkinson's disease.

The preliminary results, presented in abstract form at recent meetings, showed a slower progression of the disease among individuals with high blood urate.

"It is still uncertain whether urate exerts a neuroprotective effect, but approaches to elevating urate levels are nonetheless worth considering as a potential neuroprotective strategy," said Ascherio.

"But elevating blood urate increases the risk of kidney stones and may have adverse cardiovascular effects and should only be attempted in the context of a closely monitored randomized trial until beneficial effects are proven," he added.

The study was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Kinetics Foundation and the Intramural Research Program of the National Institutes of Health/National Institute of Environmental Health Sciences.

The findings were published online on June 20, 2007 in The American Journal of Epidemiology and will appear in an upcoming print issue of the journal.


Related medicine news :

1. Urate Reduces the Risk of Parkinsons Disease
2. Levels Of Blood Proteins May Help Heart Disease Care
3. Elevated Ozone Levels Hurt Sperm Count
4. Elevating Manganese Levels hold back HIV
5. High Levels of Protein Linked to Brain Shrinkage
6. Chickens Found To Have High Levels of Arsenic
7. Low Protein Levels A Possible Indicator For A Miscarriage
8. Low Testosterone Levels the Cause Of Depression In Men
9. Weather Found To Play An Important Role In Cholesterol Levels
10. Education Levels Found To Predict Stress
11. Effective Control Of Blood Sugar Levels
Post Your Comments:

(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: